Shares of Nasus Pharma Ltd. (NYSEAMERICAN:NSRX – Get Free Report) fell 2% on Thursday . The company traded as low as $2.95 and last traded at $2.97. 18,456 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 140,966 shares. The stock had previously closed at $3.03.
Wall Street Analysts Forecast Growth
Separately, Citizens Jmp dropped their price objective on shares of Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating for the company in a report on Thursday, March 26th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $18.00.
Get Our Latest Stock Report on NSRX
Nasus Pharma Trading Down 2.7%
Nasus Pharma Company Profile
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
See Also
- Five stocks we like better than Nasus Pharma
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
